Ticlopidine hydrochloride 250 mg
RxNorm 328741

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 328741 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: ticlopidine hydrochloride 250 mg.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCDC
Ticlopidine hydrochloride 250 mg
AUI:12276565

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDC

Semantic Clinical Drug Component (SCDC):
Ticlopidine hydrochloride 250 mg
(Atom ID: 12276565)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
ticlopidine hydrochloride 250 MG
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
328741
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12276565
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCDC
Semantic Clinical Drug Component (Ingredient + Strength)
Source Code
328741
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN BOSS STRENGTH DENOM UNIT
1
RXN Boss Strength Denom Unit
RXN BOSS STRENGTH DENOM VALUE
1
RXN Boss Strength Denom Value
RXN BOSS STRENGTH NUM UNIT
MG
RXN Boss Strength Num Unit
RXN BOSS STRENGTH NUM VALUE
250
RXN Boss Strength Num Value
RXN IN EXPRESSED FLAG
P
Strength Expressed As Precise Flag
RXN STRENGTH
250 MG
Strength plus unit of SCDC

Patient Education

Ticlopidine


Ticlopidine is used to reduce the risk of stroke in people who have had a stroke or have had warning signs of a stroke and who cannot be treated with aspirin. Ticlopidine is also used along with aspirin to prevent blood clots from forming in coronary stents (metal tubes surgically placed in clogged blood vessels to improve blood flow). It works by preventing platelets (a type of blood cell) from collecting and forming clots.
[Learn More]


Blood Thinners


Blood thinners are medicines that prevent blood clots from forming. They also keep existing blood clots from getting larger. Clots in your arteries, veins, and heart can cause heart attacks, strokes, and blockages. You may take a blood thinner if you have

There are two main types of blood thinners. Anticoagulants such as heparin or warfarin (also called Coumadin) slow down your body's process of making clots. Antiplatelet drugs, such as aspirin, prevent blood cells called platelets from clumping together to form a clot.

When you take a blood thinner, follow directions carefully. Blood thinners may interact with certain foods, medicines, vitamins, and alcohol. Make sure that your health care provider knows all of the medicines and supplements you are using. You will probably need regular blood tests to check how well your blood is clotting. It is important to make sure that you're taking enough medicine to prevent clots, but not so much that it causes bleeding.


[Learn More]


* Please review the disclaimer below.